News

RenovoRx Welcomes Acclaimed Oncologist to Scientific Board

RenovoRx Welcomes Acclaimed Oncologist to Scientific Board

RenovoRx Boosts Scientific Expertise with New Board Member

RenovoRx, Inc. (NASDAQ: RNXT), a pioneering life sciences company focused on advancing targeted oncology therapies, is excited to announce the addition of Dr. Thierry de Baère, an acclaimed interventional oncologist, to its Scientific Advisory Board (SAB). This strategic move underscores the company’s dedication to enhancing its therapeutic approaches and improving patient outcomes.

Introducing Dr. Thierry de Baère

Dr. de Baère serves as the Head of the Interventional Radiology Unit at Gustave Roussy Cancer Centre. His clinical expertise includes minimally invasive treatment options—ranging from ablation and intra-tumoral immunotherapy to intra-arterial chemotherapy. His focus on cancers affecting the lungs, kidneys, liver, and gastrointestinal tract aligns well with RenovoRx's mission to develop effective solutions for complex cancer treatments.

Significant Contributions to Interventional Oncology

With an impressive portfolio boasting over 400 peer-reviewed publications and more than 22,000 citations, Dr. de Baère has made significant strides in interventional oncology. He has held influential roles in multiple scientific committees and received elite recognitions, including the CIRSE Gold Medal in 2019 and the CIRSE Innovation Award in 2020. His extensive knowledge will play a crucial role in guiding RenovoRx’s initiatives in targeted therapies and enhancing the scope of their innovative platform.

Enhancing Targeted Therapy with TAMP

RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to optimize drug delivery directly to tumor sites, minimizing side effects. This innovative approach provides a promising alternative to traditional systemic therapies. Dr. de Baère’s involvement will undoubtedly bolster the potential of the TAMP platform as the company explores deeper into locoregional cancer therapies.

Future Directions and Goals

As RenovoRx continues to navigate the complexities of oncology treatment, the addition of Dr. de Baère to the SAB marks a pivotal enhancement to its research and clinical strategy. Dr. Ramtin Agah, the Chief Medical Officer of RenovoRx, expressed enthusiasm in having such a distinguished expert join their team, highlighting the value of Dr. de Baère's experience in improving outcomes for patients with challenging tumors.

About RenovoRx, Inc.

RenovoRx, Inc. (NASDAQ: RNXT) is at the forefront of developing cutting-edge oncology therapies, particularly through its innovative RenovoCath device. With FDA clearance, RenovoCath is poised to fulfill critical medical needs by facilitating effective drug delivery systems, making strides toward enhancing patient safety and therapeutic efficacy.

Innovative Trials and Future Products

Currently, RenovoRx is also advancing its investigational drug-device combination oncology product, designed to deliver intra-arterial gemcitabine via RenovoCath. This initiative is a part of the ongoing Phase III TIGeR-PaC trial—a cornerstone in the company's strategy to address severe needs in cancer care. Recognized as an Orphan Drug for pancreatic and bile duct cancers, RenovoCath stands to secure market exclusivity subject to FDA approval.

Commercial Advancements

RenovoRx has made strides in commercializing its TAMP technology. The company recently confirmed the receipt of its first commercial orders for RenovoCath devices, which indicates robust demand from various medical institutions, including several well-respected cancer centers. As they continue to expand their market presence, RenovoRx is also poised to generate revenue through innovative partnerships and strategies in the medical device landscape.

Frequently Asked Questions

What role will Dr. de Baère play at RenovoRx?

Dr. Thierry de Baère will contribute his expertise to the Scientific Advisory Board, guiding the development of RenovoRx's oncological therapies and platforms.

What is the Trans-Arterial Micro-Perfusion (TAMP) therapy?

TAMP is a patented therapy platform by RenovoRx designed to enhance targeted drug delivery directly to tumors, reducing systemic side effects.

How will the addition of Dr. de Baère benefit RenovoRx?

His vast knowledge and experience in interventional oncology can strengthen RenovoRx's clinical strategies and research in challenging cancer treatments.

What innovative products is RenovoRx working on?

RenovoRx is currently evaluating a drug-device combination oncology candidate involving gemcitabine delivered via its RenovoCath device under a Phase III clinical trial.

How does RenovoRx plan to expand its market presence?

RenovoRx is focused on commercializing its TAMP technology and has received positive signals from several medical institutions for its RenovoCath devices.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 65

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 40

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 33

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 159

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 47

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 23

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 104

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 116

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 77

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Review iRobot Class Action Details Amid Losses

Updated Category News Views 180

Class Action Lawsuit Against iRobot: What Investors Need to Know Bragar Eagel & Squire, P.C., an established law firm known for representing investors, is currently addressing losses incurred by shareholders of iRobot Corporation (IRBT). The firm is encouraging affected investors to reach out and discuss their legal options moving forward. Details of the Class Action...

Continue Reading
Customer Loyalty Solutions Market Poised for Significant Growth

Updated Category News Views 223

Customer Loyalty Solutions Market Poised for Significant Growth Recently, a leading market intelligence firm has conducted a comprehensive analysis of the global Customer Loyalty Solutions (CLS) Market, revealing a promising trajectory toward a compound annual growth rate (CAGR) of 11.8% projected through 2030. This analysis aims to provide companies with the strategic...

Continue Reading
Armada Hoffler Properties Reports Strong Q4 Earnings Growth

Updated Category News Views 218

Armada Hoffler Properties Highlights Strong Fourth Quarter Performance Armada Hoffler Properties, Inc. (NYSE: AHH) recently shared its financial results for the fourth quarter of the fiscal year. This announcement underscored the company's robust performance, demonstrating a commitment to growth and stability. Key Financial Metrics The company reported a net income of...

Continue Reading
Hillman Solutions Corp. Earnings Call Scheduled for November

Updated Category News Views 143

Hillman Solutions Corp. Announces Earnings Conference Call Hillman Solutions Corp. (NASDAQ: HLMN), a recognized leader in providing hardware and merchandising solutions, has scheduled a conference call to review its financial results for the thirteen and thirty-nine weeks ending September 27, 2025. This much-anticipated call will take place on November 4, starting at 8:30...

Continue Reading
Investigation Initiated into Abacus Global Management, Inc.

Updated Category News Views 428

Investigation Initiated into Abacus Global Management, Inc. Robbins Geller Rudman & Dowd LLP is spearheading an investigation into potential violations of U.S. federal securities laws concerning Abacus Global Management, Inc. (NASDAQ: ABL). The focus of this inquiry revolves around whether the company and some of its key executives delivered misleading statements or...

Continue Reading